Clinical Features of Non-Alcoholic Fatty Liver Disease in the Non-Lean Population.


Journal

Obesity facts
ISSN: 1662-4033
Titre abrégé: Obes Facts
Pays: Switzerland
ID NLM: 101469429

Informations de publication

Date de publication:
2023
Historique:
received: 31 10 2022
accepted: 17 04 2023
medline: 30 10 2023
pubmed: 26 5 2023
entrez: 26 5 2023
Statut: ppublish

Résumé

The prevalence of non-alcoholic fatty liver disease (NAFLD) in non-lean patients is significantly increased, and obesity significantly increases the risk of cirrhosis and HCC in NAFLD patients. However, whether there is a difference in clinical manifestations of NAFLD between overweight and obesity remains unclear. The objective of this study was to assess the clinical and histological features of NAFLD among a non-lean population. Current study enrolled consecutive non-lean (body mass index [BMI] >23 kg/m2) patients with NAFLD and available liver biopsy results. Patients were stratified by BMI into two groups for the comparison of their clinical and histological variables, which included the overweight (BMI 23∼<28 kg/m2) and the obese (BMI ≥28 kg/m2). Risk factors for moderate to severe fibrosis (stage >1) were also analyzed through the logistic regression model. Among 184 non-lean patients with metabolic-associated fatty liver disease enrolled, 65 and 119 were overweight and obese, respectively. Patients in the obesity group had a significantly lower level of gamma-glutamyl transpeptidase, higher levels of platelet, glucose, prothrombin time, and more common of moderate to severe inflammatory activity when compared to those in the overweight group. However, a significant low frequency of moderate to severe fibrosis was found in the obesity group versus the overweight group (19.33% vs. 40.00%, p = 0.002). Binary logistics regression analysis of fibrosis found that aspartate transaminase (AST), BMI, alanine transaminase (ALT), and cholesterol (CHOL) were independent predictors for moderate to severe fibrosis in non-lean patients with NAFLD. Compared with the traditional fibrosis-4 (AUC = 0.77) and aminotransferase to platelet ratio index (AUC = 0.79) indexes, the combined index based on AST, BMI, ALT, and CHOL was more accurate in predicting moderate to severe fibrosis in non-lean patients with NAFLD (AUC = 0.87). Clinical and histological features differed between obesity and overweight patients with NAFLD. When compared to the traditional serum markers, the combination index including AST, BMI, ALT, and CHOL provided a better model to predict moderate to severe fibrosis in non-lean patients with NAFLD.

Identifiants

pubmed: 37231905
pii: 000530845
doi: 10.1159/000530845
pmc: PMC10601616
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

427-434

Informations de copyright

© 2023 The Author(s). Published by S. Karger AG, Basel.

Références

Am J Gastroenterol. 2019 Jun;114(6):916-928
pubmed: 31169533
Lab Invest. 2010 Feb;90(2):245-56
pubmed: 19949375
Indian Pediatr. 2017 Oct 15;54(10):825-829
pubmed: 28699612
Platelets. 2010;21(1):29-32
pubmed: 19947902
Zhonghua Gan Zang Bing Za Zhi. 2013 Feb;21(2):116-20
pubmed: 23663883
Intern Med J. 2020 Sep;50(9):1038-1047
pubmed: 31760676
Lab Invest. 2015 Aug;95(8):914-24
pubmed: 26097999
BMC Pediatr. 2021 Mar 12;21(1):122
pubmed: 33711964
Postgrad Med. 2021 Apr;133(3):299-306
pubmed: 32921191
Endocr Pract. 2020 Apr;26(4):444-453
pubmed: 31968197
Diabetes Metab Syndr Obes. 2022 Feb 09;15:383-394
pubmed: 35177915
Liver Int. 2011 Feb;31(2):176-83
pubmed: 21134109
Hepatol Int. 2020 Dec;14(6):889-919
pubmed: 33006093
Gastroenterology. 2020 May;158(7):1999-2014.e1
pubmed: 32044314
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
Medicine (Baltimore). 2021 Feb 12;100(6):e24743
pubmed: 33578624
Am J Physiol Endocrinol Metab. 2020 Nov 1;319(5):E827-E834
pubmed: 32893671
J Hepatol. 2020 Jul;73(1):202-209
pubmed: 32278004
J Hepatol. 2014 Jul;61(1):98-106
pubmed: 24657401
Hepatology. 2016 Nov;64(5):1774-1784
pubmed: 26934463
J Assoc Physicians India. 2022 Apr;70(4):11-12
pubmed: 35443531
Can J Gastroenterol Hepatol. 2017;2017:6070135
pubmed: 29464178
Liver Int. 2020 Sep;40(9):2082-2089
pubmed: 32478487
Indian J Endocrinol Metab. 2013 Jul;17(4):665-71
pubmed: 23961483
World J Gastroenterol. 2021 Sep 14;27(34):5753-5763
pubmed: 34629799
Expert Rev Gastroenterol Hepatol. 2018 May;12(5):491-502
pubmed: 29609501

Auteurs

Min-Ran Li (MR)

Division of Infectious Disease, The First Affiliated Hospital of Jinan University, Guangzhou, China, muziran@126.com.

Jin-Zhong Li (JZ)

Division of Infectious Disease, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Jie-Ying Li (JY)

Division of Infectious Disease, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Cun-Chuan Wang (CC)

Bariatric and Metabolic Surgery Center, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Rui-Kun Yuan (RK)

Division of Infectious Disease, The Sixth Affiliated Hospital of Jinan University, Dongguan, China.

Li-Hong Ye (LH)

Division of Pathology, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China.

Yun-Yan Liu (YY)

Division of Liver Disease, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China.

Xu-Jing Liang (XJ)

Division of Infectious Disease, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Hai-Cong Zhang (HC)

Division of Pathology, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China.

Zhi-Quan Liu (ZQ)

Division of Pathology, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China.

Dong-Yu Zeng (DY)

Division of Infectious Disease, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Xue-Dong Zhang (XD)

Autobio Diagnostics Co., Ltd, Zhengzhou City, China.

De-Hua Wang (DH)

Division of Liver Disease, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China.

Jun-Qing Li (JQ)

Division of Liver Disease, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China.

Tao-Yuan Li (TY)

Division of Infectious Disease, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Liu Yang (L)

Division of Infectious Disease, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Yang Cao (Y)

Division of Infectious Disease, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Yun Pan (Y)

Division of Infectious Disease, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Xun-Ge Lin (XG)

Division of Infectious Disease, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Calvin Q Pan (CQ)

Department of Infectious Disease, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Division of Gastroenterology and Hepatology, NYU Langone Health, NYU Grossman School of Medicine, New York, New York, USA.

Er-Hei Dai (EH)

Division of Liver Disease, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China.

Zhi-Yong Dong (ZY)

Bariatric and Metabolic Surgery Center, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH